[Monitoring patients with chronic hepatitis during and after therapy]

Area of Science:

• Hepatology
• Virology
• Public Health

Context:

• Hepatitis C (HCV) and Hepatitis B (HBV) are significant global health concerns.
• Chronic HBV infection is a primary cause of liver cancer and mortality.
• Coinfection with HIV is common and increases liver disease progression risk.

Purpose:

• To outline appropriate screening and monitoring strategies for Hepatitis C and B.
• To emphasize the importance of assessing disease severity and treatment response.
• To highlight the need for early hepatocellular carcinoma (HCC) detection in at-risk populations.

Summary:

• Liver biopsy is the gold standard for assessing Hepatitis C severity, but AST, ALT, and HCV RNA levels are crucial for monitoring treatment response.
• HCV screening should be limited to high-risk individuals; general screening is not advised.
• For chronic HBV, monitoring viral markers (HBsAg, HBeAg, HBV DNA) is essential before and after antiviral therapy. PCR is used for HBV DNA monitoring, and YMDD mutation testing is vital for lamivudine-treated patients.
• Hepatocellular carcinoma (HCC) surveillance in cirrhotic patients involves alpha-fetoprotein (AFP) and liver sonography every six months, with upper GI endoscopy recommended periodically.
• While ultrasound and AFP aid HCC detection, their reliability is limited.

Impact:

• Provides evidence-based guidelines for managing chronic viral hepatitis.
• Aims to improve patient outcomes by optimizing screening, treatment monitoring, and early cancer detection.
• Highlights the critical role of viral load and genotype testing in guiding therapy and assessing response.
• Emphasizes the need for tailored monitoring protocols for different hepatitis viral infections and coinfections.